Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024 10:42:36
CytoTools (T5OG.DE, Xetra)
Závěr k 28.3.2024 Změna (%) Změna (EUR) Objem obchodů (EUR)
0,374 23,18 0,07 1 116
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostibioXXmed AG
TickerT5O
Kmenové akcie:Ordinary Shares
RICT5O.DE
ISINDE000A0KFRJ1
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky30.06.2023
Počet zaměstnanců k 31.12.2022 1
Akcie v oběhu k 30.06.2023 5 137 498
MěnaEUR
Kontaktní informace
UliceRiedstrasse 2
MěstoDARMSTADT
PSČ64295
ZeměGermany
Kontatní osobaBruno Rosen
Funkce kontaktní osobyMember of the Management Board
Telefon4961 519 515 812
Fax4961519515813
Kontatní telefon4961 519 515 812

Business Summary: bioXXmed AG, formerly CytoTools AG, is a Germany-based holding company that invests in biotechnological or medical technology companies with equity or borrowed capital. The Company holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. bioXXmed AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections.
Financial Summary: BRIEF: For the six months ended 30 June 2023, bioXXmed AG revenues increased from EUR4K to EUR12K. Net loss decreased 35% to EUR311K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other Operating Expenses decrease of 29% to EUR324K (expense), Interest and Similar Expense decrease from EUR28K (expense) to EUR0K.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSLessors of Nonfinancial Intangible Assets (except Copyrighted Works)
NAICSOffices of Other Holding Companies
NAICS2007Research and Development in Biotechnology
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)
NAICS2007Offices of Other Holding Companies
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Owners and Lessors of Other Non-Financial Assets
NAICS1997Offices of Other Holding Companies
SICCommercial Physical Research
SICPatent Owners And Lessors
SICHolding Companies, Nec



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardArne Bjoern Segler-30.09.202130.09.2021
Deputy Chairman of the Supervisory BoardRalph Bieneck-30.09.202130.09.2021
Member of the Management BoardBruno Rosen-30.09.202130.09.2021